KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Raw Materials (2016 - 2025)

Historic Raw Materials for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to $19.0 million.

  • Halozyme Therapeutics' Raw Materials fell 3799.34% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 3799.34%. This contributed to the annual value of $24.0 million for FY2024, which is 156.05% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Raw Materials stood at $19.0 million, which was down 3799.34% from $17.8 million recorded in Q2 2025.
  • Halozyme Therapeutics' Raw Materials' 5-year high stood at $30.6 million during Q3 2024, with a 5-year trough of $6.0 million in Q1 2021.
  • Its 5-year average for Raw Materials is $18.0 million, with a median of $18.4 million in 2025.
  • As far as peak fluctuations go, Halozyme Therapeutics' Raw Materials soared by 13750.25% in 2023, and later crashed by 3799.34% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Raw Materials stood at $10.7 million in 2021, then increased by 29.24% to $13.8 million in 2022, then soared by 71.45% to $23.6 million in 2023, then grew by 1.56% to $24.0 million in 2024, then fell by 21.05% to $19.0 million in 2025.
  • Its Raw Materials was $19.0 million in Q3 2025, compared to $17.8 million in Q2 2025 and $18.4 million in Q1 2025.